CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
2026 A. Gupta, A. Gazzo, P. Selenica, A. Safonov, F. Pareja, E.M. Da Silva, D.N. Brown, H. Shao, Y. Zhu, J. Patel, J. Blanco-Heredia, B. Stefanovska, M.A. Carpenter, Y. Chen, I. Vegas, X. Pei, D. Frosina, A.A. Jungbluth, M. Ladanyi, G. Curigliano, B. Weigelt, N. Riaz, S.N. Powell, P. Razavi, R.S. Harris, J.S. Reis-Filho, A. Marra, S. Chandarlapaty
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209]
2026 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Proton therapy in breast cancer: bridging medical and radiation oncology
2026 D. Alterio, S. Dicuonzo, M. Zaffaroni, M.G. Vincini, P. Zagami, C. Criscitiello, F. Braga, E. Milovanova, M.C. Leonardi, P. Veronesi, A.M. Kirby, R. Orecchia, G. Curigliano, B.A. Jereczek-Fossa
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
2026 P. Tomasini, Y. Wang, Y. Li, E. Felip, L. Wu, J. Cui, B. Besse, A.I. Spira, J.W. Neal, K. Goto, C.S. Baik, M.E. Marmarelis, G. Curigliano, E. Ichihara, Y. Zhang, J. Lee, S. Lee, J.C. Yang, S. Michels, Z. Anastasiou, J.C. Curtin, X. Lyu, J. Mahoney, L. Demirdjian, C.S. Meyer, Y. Zhang, I. Leconte, P. Lorenzini, R.E. Knoblauch, L. Trani, M. Baig, J.M. Bauml, B.C. Cho
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
2026 G. Martini, S. Napolitano, D. Ciardiello, L.B. Bielo, E. Martinelli, T. Troiani, M.G. Zampino, N. Fazio, G. Curigliano, F. Ciardiello
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer
2026 A. Brufsky, R.M. Layman, X. Liu, B. Li, L. Mcroy, A.B. Cohen, M. Estevez, P. Cottu, G. Curigliano, H.S. Rugo
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
2026 R. Scafetta, R. Troiano, C. Gullotta, A. Guarino, C. Fiore, L. Sisca, E. Speziale, M. Donato, S. Foderaro, F. Venuti, F.A. Vilardi, V. Ricozzi, M. Iuliani, S. Simonetti, S. Cavaliere, A. Cortellini, A.L. Cesa, A. Botticelli, S. Scagnoli, S. Pisegna, C. Criscitiello, R. Pedersini, C. Sposetti, E. Tiberi, G. D'Auria, M. Vergati, M. Mazzotta, R. Caputo, A. Verrazzo, O. Garrone, F. Domati, C. Piombino, F.S.D. Lisa, L. Filomeno, T. Arcuri, F. Puce, F. Riva, M. Palleschi, M. Sirico, M. Piras, L.S. Stucci, D.D. Lisi, P. Orsaria, A. Grasso, E. Ippolito, S. Ramella, L. Visani, L. Livi, S. Gori, L. Rossi, I. Meattini, B. Tagliaferri, O. Caffo, M.V. Bonomo, I. Portarena, A. Irelli, E. Cretella, C. Porta, G. Bianchini, M.A. Fabbri, U.D. Giorgi, P. Vici, A. Toss, F. Ruatta, M.D. Laurentiis, F. Villa, R. Berardi, M. Minelli, V. Altomare, C. Vernieri, G. Curigliano, A. Chirco, S. D'Alessandro, B. Vincenzi, G. Tonini, D. Santini, F. Pantano
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
2026 H. Wildiers, V. Adam, S. O'Reilly, J. Van Cauwenberge, A. Arahmani, C.L. Arteaga, P.L. Bedard, J. Bliss, P. Boussis, E. Brain, M. Buyse, C. Caballero, D. Cameron, F. Cardoso, E. Carrasco, A. Casas, B. Chua, G. Curigliano, A. Demichele, L. Esserman, G. Floris, M.P. Goetz, T. Goulioti, B. Haibe-Kains, C. Hodgdon, M. Ignatiadis, M. Kok, D. Lacombe, B. Linderholm, S. Loi, C.J. Lord, M. Mackenzie, J. Maues, L. Meheus, J. Needham, P. Neven, H. Parsons, M. Piccart, L. Pusztai, E. Razis, S. Saji, E. Schumacher-Wulf, G.S. Sonke, T. Spanic, I.F. Tannock, A. Tutt, A. Urruticoechea, L. Van 'T Veer, I. Vaz-Luis, G. Werutsky, D. Yee, K. Zaman, C. Desmedt
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2026 N. Bianco, C. Valenza, M. Milano, R. Multinu, E. Battaiotto, M. Cavallone, G. Malvezzi, D. Trapani, P. Della Vigna, G. Bonomo, G.M. Varano, D. Maiettini, M.G. Pitoni, C. Sangalli, E. Munzone, G. Curigliano, M.A. Colleoni, F. Orsi
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database
2026 C. Aristei, M. Tomatis, A. Ponti, L. Marotti, N.M.L. Battisti, K. Leung Cheung, O.J. Hartmann, I.T. Rubio, D. Santini, F. Sardanelli, E. Senkus, P. Van Dam, G. Curigliano
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
2026 D. Trapani, S.K. Deshmukh, T. Samec, S. Wu, J. Xiu, P. Walker, D.L. Abravanel, P. Advani, P.M. Spanheimer, N.U. Lin, G. Curigliano, S.L. Graff, M. Lustberg, G.W. Sledge, S.M. Tolaney, J.P. Leone
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
2026 D. Ciardiello, G. Martini, L. Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2026 C. Saura, J. Cortés, S. Modi, S. Kim, E. Hamilton, S.A. Hurvitz, I.E. Krop, G. Curigliano, H. Iwata, S. Im, P. Herbolsheimer, M. Karnoub, A. Boran, Y. Kuwahara, A. Egorov, F. André
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
2026 K.L. Jhaveri, N.M. Iyengar, N.C. Turner, H.S. Rugo, J. O'Shaughnessy, C.H. Barrios, G. Curigliano, F. André, S. Im, M.D. Goncalves, M.E. Lacouture, P.A. Fasching, R. Leung
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
2026 G. Curigliano, X. Hu, R. Dent, K. Yonemori, C.H. Barrios, J. Pierga, F. Puglisi, J. Ferrero, K.H. Jung, N.A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
2026 L. Boscolo Bielo, D. Trapani, P. Razavi, S. Chandarlapaty, Y. Zhan, G. Curigliano
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases
2026 R. Scafetta, M. Donato, C. Gullotta, A. Guarino, C. Fiore, L. Sisca, E. Speziale, R. Troiano, S. Foderaro, F. Venuti, F.A. Vilardi, V. Ricozzi, M. Iuliani, S. Simonetti, S. Cavaliere, A. Cortellini, A. La Cesa, A. Botticelli, S. Scagnoli, S. Pisegna, C. Criscitiello, A. Chirco, S. D'Alessandro, R. Pedersini, C. Sposetti, E. Tiberi, G. D'Auria, M. Vergati, M. Mazzotta, R. Caputo, A. Verrazzo, M.G. Rossino, F. Domati, C. Piombino, F.S. Di Lisa, L. Filomeno, T. Arcuri, F. Puce, F. Riva, M. Palleschi, M. Sirico, M. Piras, L.S. Stucci, D. De Lisi, P. Orsaria, A. Grasso, E. Ippolito, S. Ramella, L. Visani, N. Bertini, I. Bonaparte, S. Gori, L. Rossi, I. Meattini, B. Tagliaferri, O. Caffo, M.V. Bonomo, I. Portarena, A. Irelli, E. Cretella, C. Porta, G. Bianchini, M.A. Fabbri, U. De Giorgi, P. Vici, A. Toss, O. Garrone, M. De Laurentiis, F. Villa, R. Berardi, M. Minelli, V. Altomare, C. Vernieri, G. Curigliano, B. Vincenzi, G. Tonini, D. Santini, F. Pantano
Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer
2026 C. Corti, T. Li, A.R. Martin, M.E. Hughes, T. Parker, T.S. Duporte, G. Curigliano, T.A. King, E.A. Mittendorf, N.U. Lin, N. Tayob, S.M. Tolaney
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization
2026 G. Curigliano, L. Marotti, C. Barrios, N.M.L. Battisti, K.L. Cheung, S. Chia, S.L. Graff, O.J. Hartmann, I. Rubio, D. Santini, F. Sardanelli, E. Senkus, P. Van Dam, M. Walker, J. Wu, C. Aristei